 RANDOMIZED PHASE II STUDY OF IXABEPILONE ALONE AND IXABEPILONE PLUS CETUXIMAB AS FIRST-LINE TREATMENT FOR FEMALE SUBJECTS WITH TRIPLE NEGATIVE LOCALLY ADVANCED NON-RESECTABLE ANDOR METASTATIC BREAST CANCER: 